Newer anti‑seizure medications (ASMs) offer better seizure control, fewer side effects, and more targeted mechanisms than many older drugs. Several of these medications have shown major breakthroughs for patients with focal epilepsy, generalized epilepsy, and genetic epilepsies.
1. Cenobamate (Xcopri®)
FDA approval: 2019 Used for: Focal epilepsy in adults Why it matters:
- One of the most effective new ASMs for drug‑resistant focal epilepsy
- Up to 20% of patients became seizure‑free in trials — unusually high for refractory epilepsy
- Works through dual mechanisms:
- Enhances GABA‑A inhibition
- Inhibits persistent sodium currents
Common side effects: Sleepiness, dizziness, drug‑drug interactions Notes: Must be titrated slowly to avoid DRESS (rare but serious rash)
2. Fenfluramine (Fintepla®)
FDA approval: 2020 Used for:
- Dravet syndrome
- Lennox‑Gastaut syndrome
Why it matters:
- Reduces seizure frequency significantly
- May reduce SUDEP risk in Dravet syndrome
- Works by increasing serotonin signaling
Common side effects: Appetite loss, fatigue Monitoring: Requires periodic echocardiograms (rare cardiac effects)
3. Brivaracetam (Briviact®)
FDA approval: 2016 (increasing use in 2020s) Used for: Focal seizures (ages 1 month and older) Why it matters:
- A more selective version of levetiracetam
- Fewer mood/behavioral side effects than Keppra for many patients
Common side effects: Sleepiness, dizziness
4. Cannabidiol (Epidiolex®)
FDA approval: 2018 (expanded indications since) Used for:
- Dravet syndrome
- Lennox‑Gastaut syndrome
- Tuberous sclerosis complex
Why it matters:
- First FDA‑approved plant‑derived cannabinoid
- Non‑sedating option for genetic epilepsies
Common side effects: Diarrhea, appetite loss, elevated liver enzymes Monitoring: Liver function tests required
5. Everolimus (Afinitor®)
Used for: Tuberous sclerosis complex (TSC‑associated seizures) Why it matters:
- Targets the mTOR pathway, treating the underlying mechanism of TSC
- Helps reduce seizure frequency and tumor growth
Common side effects: Mouth sores, infections Monitoring: Blood levels, kidney function
6. XEN1101 (Investigational – Not yet FDA‑approved)
Used for: Drug‑resistant focal epilepsy Why it matters:
- A next‑generation potassium channel opener
- Phase 2b trials show ~53% median seizure reduction
- Appears safer than older potassium‑channel drugs (e.g., ezogabine)
Common side effects: Dizziness, sleepiness
7. Z944 (Investigational – T‑type calcium channel blocker)
Used for: Absence epilepsy (early trials) Why it matters:
- More targeted than ethosuximide
- Potential for fewer GI side effects
8. Perampanel (Fycompa®)
FDA approval: 2012 (but expanded use in 2020s) Used for: Focal and generalized tonic‑clonic seizures Why it matters:
- First ASM to target AMPA receptors (glutamate pathway)
- Helpful for patients who fail sodium‑channel drugs
Common side effects: Irritability, dizziness
9. Lacosamide XR (Vimpat XR®)
FDA approval: XR formulation expanded in 2020s Used for: Focal epilepsy Why it matters:
- Once‑daily dosing
- Fewer side effects than older sodium‑channel blockers